newsfilter
← Latest News
Business Wire·

Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247

Dosing of first participant in a Phase 1 clinical trial of SAT-3247 anticipated in Q3 2024 Satellos Bioscience Inc. ("Satellos" or the "Company") (TSX:MSCL, OTCQB:MSCLF), a public biotech company developing new small